Actively Recruiting
Cardiotoxicity in Breast Cancer Patients
Led by Helwan University · Updated on 2025-09-22
40
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug. Aim of the study: Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity. The main questions it aims to answer are: 1. Does the drug lower the cardiotoxicity which induced by anthracyclines? 2. What medical problems do participants have when taking dapagliflozin drug? Treatment 1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination. 2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.
CONDITIONS
Official Title
Cardiotoxicity in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathologically confirmed invasive breast carcinoma
- Patients scheduled for anthracycline-containing adjuvant chemotherapy or new anthracycline adjuvant therapy
- Kidney function with estimated glomerular filtration rate (eGFR) greater than 30 mL/minute per 1.73 m2
- Left ventricular ejection fraction (LVEF) greater than 50%
- Age between 18 and 60 years old
You will not qualify if you...
- Any heart condition that prevents the use of anthracyclines, such as heart failure, arrhythmia, stroke, or heart attack
- Prior treatment with anthracycline chemotherapy or other cardiotoxic chemotherapy regimens
- Pregnancy or breastfeeding
- Use of other cardiotoxic medications
- Having diabetic ketoacidosis or type 1 diabetes mellitus
- Radiation therapy to the chest area including the heart
- Refusal to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Al demerdash hospital at oncology departement
Cairo, Cairo Governorate, Egypt, 202
Actively Recruiting
Research Team
S
Shimaa Nabil Abd elaziz Hassanein, bachelor
CONTACT
S
Sara Mohamed Mohamed, Lecturer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here